Loading stock data…
Passage Bio (PASG)
$4.85+0.15 (+3.19%)
Market ClosedLast close Jun 29
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Passage Bio, Inc. in the Healthcare sector is trading at $4.85 with a market capitalization of $18M. Wall Street consensus targets $15.50 (2 analysts), implying a +219.6% move over the next 12 months. The stock is currently near its 52-week low of $3.29, remaining 42.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +219.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.88M↑ | -$10.34M↓ | -$8.65M↑ | -$10.33M↑ | -$13.82M |
| Net Income | -$7.56M↑ | -$12.98M↓ | -$7.75M↑ | -$9.38M↑ | -$15.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficienc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.96M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-320.59%
Volume
Today's trading volume
102,781
Recent News
Remix to go public in reverse merger with once high-flying Passage Bio
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?
Passage Bio said on Wednesday that it will merge with privately held Remix Therapeutics.
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the